Search

Your search keyword '"V. Pace Palitti"' showing total 14 results

Search Constraints

Start Over You searched for: Author "V. Pace Palitti" Remove constraint Author: "V. Pace Palitti" Topic hepatology Remove constraint Topic: hepatology
14 results on '"V. Pace Palitti"'

Search Results

1. Prediction of response to obeticholic acid in primary biliary cholangitis: Development and validation of the OCA response score (ORS)

2. Long-term results from the Italian real-world experience on obeticholic acid treatment in primary biliary cholangitis: The RECAPITULATE study

3. Predictors of Serious Adverse Event and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis under Obeticholic Acid

4. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C

5. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

6. Real-world data on the treatment of primary biliary cholangitis with obeticholic acid in Italy: the CLEO-AIGO OCA cohort

7. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance

8. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

9. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy

10. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy

11. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies

12. Natural HCV resistance is common in Italy and differently associated to genotypes

13. Daclatasvir/sofosbuvir and ribavirin 800mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience

14. Impact of different Sofosbuvir-based direct acting antiviral (DAA) regimen in elderly cirrhotic patients: A real world experience from CLEO Group

Catalog

Books, media, physical & digital resources